Skip to main content
Equibles
ENTA logo

ENTA · Enanta Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track ENTA — free

Use ENTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.30 -0.88 (-7.22%) Q2 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$354.75M
Shares
29.13M
Volume · Oct 28 116.86K Avg daily vol (3M) 243.4K

Enanta Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Enanta Pharmaceuticals Inc (ENTA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-06-04
Enanta Pharmaceuticals Inc (ENTA) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY24 · Q4
2024-11-25
Enanta Pharmaceuticals Inc (ENTA) Q4 2024 Earnings Call
Revenue
$14.61M*
▼ 22.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-08-05
Enanta Pharmaceuticals Inc (ENTA) Q3 2024 Earnings Call
Revenue
$17.97M
▼ 4.9% YoY
Diluted EPS
$-1.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2024 Earnings Call Transcript
Balanced tone RSV pipeline (zelicapavir/EDP-938 and EDP-323) Immunology / CSU oral KIT inhibitor program Pfizer patent litigation
Revenue
$17.05M
▼ 4.2% YoY
Diluted EPS
$-1.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-02-07
Enanta Pharmaceuticals Inc (ENTA) Q1 2024 Earnings Call Transcript
Positive tone RSV program - zelicapavir (N-protein inhibitor) Immunology/CSU program RSV program - EDP-323 (L-protein inhibitor)
Revenue
$18.00M
▼ 23.7% YoY
Diluted EPS
$-1.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-11-20
Enanta Pharmaceuticals Inc (ENTA) Q4 2023 Earnings Call Transcript
Revenue
$18.93M*
▼ 6.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-08-07
Enanta Pharmaceuticals Inc (ENTA) Q3 2023 Earnings Call Transcript
Revenue
$18.89M
▼ 3% YoY
Diluted EPS
$-1.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-05-08
Enanta Pharmaceuticals Inc (ENTA) Q2 2023 Earnings Call Transcript
Revenue
$17.80M
▼ 4.9% YoY
Diluted EPS
$-1.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-02-07
Enanta Pharmaceuticals Inc (ENTA) Q1 2023 Earnings Call Transcript
Revenue
$23.59M
▼ 14.7% YoY
Diluted EPS
$-1.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-11-21
Enanta Pharmaceuticals Inc (ENTA) Q4 2022 Earnings Call Transcript
Revenue
$20.32M*
▼ 13.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-08-08
Enanta Pharmaceuticals Inc (ENTA) Q3 2022 Earnings Call Transcript
Revenue
$19.48M
▼ 9.9% YoY
Diluted EPS
$-1.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-05-09
Enanta Pharmaceuticals Inc (ENTA) Q2 2022 Earnings Call Transcript
Revenue
$18.72M
▼ 7% YoY
Diluted EPS
$-1.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-02-08
Enanta Pharmaceuticals Inc (ENTA) Q1 2022 Earnings Call Transcript
Revenue
$27.65M
▼ 12.9% YoY
Diluted EPS
$-1.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-11-22
Enanta Pharmaceuticals Inc (ENTA) Q4 2021 Earnings Call Transcript
Revenue
$23.57M*
▼ 0.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-08-05
Enanta Pharmaceuticals Inc (ENTA) Q3 2021 Earnings Call Transcript
Revenue
$21.62M
▲ 15.9% YoY
Diluted EPS
$-1.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcript
Revenue
$20.13M
▼ 27.1% YoY
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-02-08
Enanta Pharmaceuticals Inc (ENTA) Q1 2021 Earnings Call Transcript
Revenue
$31.74M
▼ 39.6% YoY
Diluted EPS
$-0.41
▼ 163.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-11-23
Enanta Pharmaceuticals Inc (ENTA) Q4 2020 Earnings Call Transcript
Revenue
$23.63M
▼ 53.9% YoY
Diluted EPS
$-1.46
▼ 431.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-08-04
Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript
Revenue
$18.65M
▼ 58% YoY
Diluted EPS
$-0.71
▼ 315.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2020 Earnings Call Transcript
Revenue
$27.62M
▼ 30.3% YoY
Diluted EPS
$-0.30
▼ 250% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-02-06
Enanta Pharmaceuticals Inc (ENTA) Q1 2020 Earnings Call Transcript
Revenue
$52.57M
▼ 24.8% YoY
Diluted EPS
$0.65
▼ 48% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 webcasts
Key facts CIK 1177648 CUSIP 29251M106 13F (30d) 15 filings 15 filers Visit website Investor relations